NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

CytoTools AG (XETRA: T5O)

 
T5O Technical Analysis
5
As on 9th Jun 2023 T5O STOCK Price closed @ 1.98 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.39 & Strong Sell for SHORT-TERM with Stoploss of 4.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

T5OSTOCK Price

Open 1.98 Change Price %
High 1.98 1 Day 0.05 2.59
Low 1.98 1 Week -0.02 -1.00
Close 1.98 1 Month -0.28 -12.39
Volume 166 1 Year -2.74 -58.05
52 Week High 5.18 | 52 Week Low 1.09
 
XETRA Germany Most Active Stocks
LHAR 2.05 -20.23%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BVBA 0.02 -60.00%
SNH 0.16 6.67%
SNH 0.16 6.67%
SNH 0.16 6.67%
AT1 1.15 5.50%
AT1 1.15 5.50%
 
XETRA Germany Top Gainers Stocks
ASKN 0.73 73.81%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
 
XETRA Germany Top Losers Stocks
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
BVBA 0.02 -60.00%
SD1 0.13 -51.85%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
CNW 0.24 -29.41%
 
 
T5O
Daily Charts
T5O
Intraday Charts
Whats New @
Bazaartrend
T5O
Free Analysis
 
T5O Important Levels Intraday
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
RESISTANCE1.98
 
T5O Forecast May 2024
4th UP Forecast4.68
3rd UP Forecast3.81
2nd UP Forecast3.28
1st UP Forecast2.74
1st DOWN Forecast1.22
2nd DOWN Forecast0.68
3rd DOWN Forecast0.15
4th DOWN Forecast-0.72
 
T5O Weekly Forecast
4th UP Forecast3.02
3rd UP Forecast2.69
2nd UP Forecast2.48
1st UP Forecast2.27
1st DOWN Forecast1.69
2nd DOWN Forecast1.48
3rd DOWN Forecast1.27
4th DOWN Forecast0.94
 
T5O Forecast2024
4th UP Forecast9.9
3rd UP Forecast7.36
2nd UP Forecast5.79
1st UP Forecast4.22
1st DOWN Forecast-0.26
2nd DOWN Forecast-1.83
3rd DOWN Forecast-3.4
4th DOWN Forecast-5.94
 
 
T5O Other Details
Segment EQ
Market Capital 33512958.00
Sector Financial Services
Industry Asset Management
Offical website >
 
T5O Address
T5O
 
T5O Latest News
 
Your Comments and Response on CytoTools AG
 
T5O Business Profile
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany. Address: Klappacher Strasse 126, Darmstadt, Germany, 64285
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service